Approved for
9-months on the following conditions: FDA shall make edits to the
race and ethnicity questions to conform to OMB standards in all
versions of the questionnaire. Upon completion of the study, FDA
shall submit a report to OMB on the response rate achieved in the
study using the methods outlined in AAPOR response rate 3, and
results of the non-response assessment.
Inventory as of this Action
Requested
Previously Approved
06/30/2005
06/30/2005
10/31/2004
1
0
1
626
0
609
0
0
0
Since 1982, FDA has surveyed the
public periodically regarding health professional counseling of
patients about prescription medications, distribution of written
medication information, and patient-initiated information seeking
about medications. This tracking study was conducted in 1982, 1984,
1992, 1994, 1995, and 1998. It is essential for FDA to continue to
conduct this survey in the Year 2001 because: (1) FDA is
responsible for objective 12.8 within the national DHHS Healthy
People 2010 initiative to assess an increase in patient medication
counseling levels to 75 by the end of the year 2004,
and.....
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.